TT3A: Minimally Invasive Aortic Solution | MedTech World Middle East 2026

Why It Matters

If validated, the device would convert a high-risk, lengthy open procedure into a catheter-based treatment, extending care to the roughly 30% of patients currently deemed inoperable and tapping a multi-billion-dollar unmet market. Successful development would reshape treatment for life‑threatening ascending aortic disease and create a clear commercial exit opportunity for investors.

Summary

TT3A, led by CEO Alexandro Pito, is developing a transcatheter combined valve-and-stent graft to treat pathologies of the ascending aorta—an area currently treatable only by complex open-heart surgery. The startup says its minimally invasive device could halve mortality and hospitalization versus surgery, and addresses a roughly 50,000-patient annual market in the US and EU valued at about $1.3 billion today and projected to reach $2.5 billion by 2030. TT3A reports positive acute in vivo results from large-animal (sheep) testing, has filed two patent applications, and is raising a $2 million seed round to fund further preclinical work with a first-in-human target in 2028 and market readiness by 2030–2032. The team is small—two full-time founders plus consultants and a clinical board—and plans to pursue expedited regulatory pathways including humanitarian device exemption.

Original Description

Watch Alessandro Pizzo, CEO of TT3A, pitch his groundbreaking minimally invasive device for the ascending aorta at the MedTech World Startup Pitch Competition, powered by Blue Goat Cyber and Ascend Clinical, during MedTech World Middle East 2026.

The ascending aorta is one of the most complex and critical parts of the cardiovascular system, with current treatments limited to highly invasive open-heart surgery. TT3A’s innovative transcatheter device combines a valve and stent graft into a single structure, aiming to reduce mortality and hospitalization by 50% and offer treatment to patients previously considered inoperable.

Alessandro shares insights on TT3A’s journey, including successful acute in vivo testing in large animal models, regulatory strategy, and the company’s plan to reach first human trials by 2028. With a potential market of $2.5 billion by 2030 in the US and EU, TT3A is positioned to redefine care for life-threatening aortic pathologies like aneurysms and dissections.

Stay updated on innovative MedTech solutions by subscribing to our channel and following the MedTech World Startup Pitch Competition highlights.

#MedTechWorld #MTWMiddleEast2026 #MedTechWorldStartupPitchCompetition #StartupPitch #TT3A #CardiovascularInnovation #AorticHealth #MinimallyInvasive #HealthcareInnovation #LifeSavingDevices